Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

Eric O Aboagye, Fiona J Gilbert, Ian N Fleming, Ambros J Beer, Vincent J Cunningham, Paul K Marsden, Dimitris Visvikis, Antony D Gee, Ashley M Groves, Laura M Kenny, Gary J Cook, Paul E Kinahan, Melvyn Myers, Larry Clarke, Experimental Cancer Medicine Centre 13 Imaging Network Group

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics.

Key Points
• [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET
• In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion
• Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.
Original languageEnglish
Pages (from-to)1465-1478
Number of pages14
JournalEuropean Radiology
Volume22
Issue number7
Early online date4 Apr 2012
DOIs
Publication statusPublished - 1 Jul 2012

Fingerprint

Positron-Emission Tomography
Clinical Trials
Neoplasms
Integrins
Perfusion
Drug Evaluation
Radiopharmaceuticals
Water
Therapeutics

Cite this

Aboagye, E. O., Gilbert, F. J., Fleming, I. N., Beer, A. J., Cunningham, V. J., Marsden, P. K., ... Experimental Cancer Medicine Centre 13 Imaging Network Group (2012). Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. European Radiology, 22(7), 1465-1478. https://doi.org/10.1007/s00330-011-2311-3

Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. / Aboagye, Eric O; Gilbert, Fiona J; Fleming, Ian N; Beer, Ambros J; Cunningham, Vincent J; Marsden, Paul K; Visvikis, Dimitris; Gee, Antony D; Groves, Ashley M; Kenny, Laura M; Cook, Gary J; Kinahan, Paul E; Myers, Melvyn; Clarke, Larry; Experimental Cancer Medicine Centre 13 Imaging Network Group.

In: European Radiology, Vol. 22, No. 7, 01.07.2012, p. 1465-1478.

Research output: Contribution to journalArticle

Aboagye, EO, Gilbert, FJ, Fleming, IN, Beer, AJ, Cunningham, VJ, Marsden, PK, Visvikis, D, Gee, AD, Groves, AM, Kenny, LM, Cook, GJ, Kinahan, PE, Myers, M, Clarke, L & Experimental Cancer Medicine Centre 13 Imaging Network Group 2012, 'Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials', European Radiology, vol. 22, no. 7, pp. 1465-1478. https://doi.org/10.1007/s00330-011-2311-3
Aboagye, Eric O ; Gilbert, Fiona J ; Fleming, Ian N ; Beer, Ambros J ; Cunningham, Vincent J ; Marsden, Paul K ; Visvikis, Dimitris ; Gee, Antony D ; Groves, Ashley M ; Kenny, Laura M ; Cook, Gary J ; Kinahan, Paul E ; Myers, Melvyn ; Clarke, Larry ; Experimental Cancer Medicine Centre 13 Imaging Network Group. / Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. In: European Radiology. 2012 ; Vol. 22, No. 7. pp. 1465-1478.
@article{6c57fa5197dd40a5be09824c51938533,
title = "Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials",
abstract = "The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. Key Points • [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET • In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion • Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.",
author = "Aboagye, {Eric O} and Gilbert, {Fiona J} and Fleming, {Ian N} and Beer, {Ambros J} and Cunningham, {Vincent J} and Marsden, {Paul K} and Dimitris Visvikis and Gee, {Antony D} and Groves, {Ashley M} and Kenny, {Laura M} and Cook, {Gary J} and Kinahan, {Paul E} and Melvyn Myers and Larry Clarke and {Experimental Cancer Medicine Centre 13 Imaging Network Group}",
year = "2012",
month = "7",
day = "1",
doi = "10.1007/s00330-011-2311-3",
language = "English",
volume = "22",
pages = "1465--1478",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

AU - Aboagye, Eric O

AU - Gilbert, Fiona J

AU - Fleming, Ian N

AU - Beer, Ambros J

AU - Cunningham, Vincent J

AU - Marsden, Paul K

AU - Visvikis, Dimitris

AU - Gee, Antony D

AU - Groves, Ashley M

AU - Kenny, Laura M

AU - Cook, Gary J

AU - Kinahan, Paul E

AU - Myers, Melvyn

AU - Clarke, Larry

AU - Experimental Cancer Medicine Centre 13 Imaging Network Group

PY - 2012/7/1

Y1 - 2012/7/1

N2 - The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. Key Points • [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET • In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion • Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.

AB - The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. Key Points • [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET • In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion • Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.

U2 - 10.1007/s00330-011-2311-3

DO - 10.1007/s00330-011-2311-3

M3 - Article

C2 - 22476502

VL - 22

SP - 1465

EP - 1478

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 7

ER -